We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Vicotex

Download Mobile App




Messenger RNA Quality Control Mechanism Explained

By Gerald M. Slutzky, PhD
Posted on 15 Nov 2016
Genomics researchers have described a mechanism that explains how molecules of messenger RNA (mRNA) are checked for accuracy before being released from the nucleus into the cytoplasm.

Export of mRNAs into the cytoplasm is a fundamental step in gene regulation processes, which undergo quality control by highly efficient mechanisms in eukaryotic cells. More...
However, it remains unclear how the aberrant mRNAs are recognized and retained inside the nucleus.

To better understand the quality control process, investigators at Berkeley National Laboratory (CA, USA) and the University of California, Berkeley (USA) used a new modeling approach for complex systems, namely the agent-based modeling (ABM) approach, to develop a minimal model of the mRNA quality control (QC) mechanism.

They reported in the November 2, 2016, online edition of the journal Scientific Reports that regulation of the affinity of RNA-binding proteins (RBPs) to export receptors along with the weak interaction between the nuclear basket protein (Mlp1 or Tpr) and RBPs were the minimum requirements to distinguish and retain aberrant mRNAs. The results showed that the affinity between Tpr and RBPs was optimized to maximize the retention of aberrant mRNAs.

The length of the mRNA strand affected the QC process. Since longer mRNAs spent more time in the nuclear basket to form a compact conformation and initiate their export, nuclear basket proteins could more easily capture and retain them inside the nucleus.

"Just like all production lines, the process of genetic information transfer and protein production is quality controlled at different stages," said senior author Mohammad Mofrad, professor of bioengineering and of mechanical engineering at the University of California, Berkeley. "To date, the exact mechanism of this quality control step has remained unclear. Some components of this machinery are dysregulated in various types of cancers. Understanding the molecular mechanism of genetic information transport and quality control would substantially improve the current knowledge about various types of cancers and other human diseases."

Related Links:
Berkeley National Laboratory
University of California, Berkeley

Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
New
Gold Member
Blood-Based Protein Biomarker Solution for Alzheimer's Disease
BG-DTi2000.
Immunofluorescence Analyzer
IFA System
Pipette Calibration System
Artel PCS®
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Graphical abstract (Pola, I., Akinyemi, T., Tan, K. et al. Nature Communications(2026). https://doi.org/10.1038/s41467-026-74971-4)

Blood Biomarker Study Reveals Population-Specific Differences in Alzheimer’s Disease

Blood-based biomarkers are emerging as tools for detecting Alzheimer’s disease–related changes without relying on advanced brain imaging or cerebrospinal fluid (CSF) analysis. However, much of the foundational... Read more

Molecular Diagnostics

view channel
Image Credit: Shutterstock

Blood Test for Lung Cancer Screening Receives FDA Breakthrough Device Designation

Lung cancer remains the leading cause of cancer death in the United States, yet only about 18% of people eligible for screening undergo low-dose computed tomography, the current guideline-recommended method.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.